3SOF

I expect about the same. Good luck to you as well if you are in it.

So you guys are just looking for a quick trade once it gets to .74?

Ohh yeah just a quick trade ... I'm already in @ 0.67 & that's also the close fo the day

if you get in @ 0.67 & out @ 0.70 with 15000 shares that's still $450 profits, right?

I didnt see any bad news to cause the drop, but someone was selling cheap in the pre market.  I just noticed at the last minute and got 2000 shares filled at .55 at about 9:29 AM lol, though I wanted more.  Anyway, here is to hoping it gets back to where it should be, so we can all profit!

Update: argh, had to get out at .56 just to keep even, sorry this isnt working out so far 

Expected news is on the table:

http://biz.yahoo.com/prnews/060903/to329.html?.v=4
New Data from Vasogen's ACCLAIM Trial in Heart Failure Presented at World Congress of Cardiology 2006
Sunday September 3, 11:33 am ET
- 31% Risk Reduction in Combined Group of Class III/IV Patients with No Prior Heart Attack and All Class II Patients -
- New Data Define Prime Target Population for Commercial Development -

I'm NOT an expert in biotechnology - can somebody understand: is this news a real GOOD news?     

Check old news:
26 June 2006 Vasogen Inc., down $1.37 at $0.48, because of the Phase III initial results:
http://biz.yahoo.com/prnews/060626/to179.html?.v=30
Vasogen Announces Initial Results from Phase III ACCLAIM Trial in Chronic Heart Failure
Monday June 26, 7:32 am ET
Study did not meet primary endpoint; Endpoint Met in NYHA Class II Patient Subgroup
------------------------------
Sold half on Fri 1 Sep @0.63 with a 7% loss 
And still holding last half of my position... we will see some action on Monday.

Good trades for all and thanks in advance for any thoughts about this news.

Last piece of news:

Vasogen New ACCLAIM Results Presented at the World Congress of Cardiology 2006 Conference Call
http://biz.yahoo.com/cc/2/72442.html

When June's gap will be filled ?
What kind of action we will see on Tuesday? 

Any thoughts will be very much appreciated
(Please, see my previous post.)

It is moving up or may be I should say it is running up.

Nice come back!

News is out: interesting point of view to the known results.

29%

http://www.3stocksonfire.org/trading/index.php?action=post;topic=2530.15;num_replies=23
"Vasogen's Celacade(TM) Shown to Significantly Reduce Time in Hospital in Prime Heart Failure Target Population"

Just got this from my news feed..

Yahoo!My Yahoo!Mail     Make Y! your home pageYahoo! SearchSearch:Welcome, agentdapper
[Sign Out, My Account]Finance Home -Help


HomeInvestingNews & CommentaryRetirement & PlanningBanking & CreditLoansInsuranceSpecial EditionsColumnistsPersonal FinanceInvesting IdeasMarketsCompany FinancesProvidersGet QuotesSymbol LookupFinance Search

       

Press Release Source: Vasogen Inc.


Vasogen's Celacade(TM) Shown to Significantly Reduce Time in Hospital in Prime Heart Failure Target Population
Wednesday September 13, 1:12 pm ET 
- New Data from the ACCLAIM Trial Presented at the Heart Failure Society of America Meeting
- Preparations Underway for FDA Meeting to Discuss Plans for Regulatory Submission in U.S. -


MISSISSAUGA, ON, Sept. 13 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that new data from the 2,400-patient ACCLAIM trial of Celacade in chronic heart failure, showed that the average days spent in hospital for cardiovascular cause was reduced by 32% in a prime heart failure target population, consisting of New York Heart Association (NYHA) Class II-IV non-ischemic cardiomyopathy patients, characterized as having no prior history of heart attack, and Class II patients with ischemic heart failure (n=1,305 patients, p=0.013). The results were presented today by Guillermo Torre-Amione MD, PhD, at the 10th Annual Scientific Meeting of the Heart Failure Society of America in Seattle, Washington. Chronic heart failure is estimated to cost the healthcare system $25 billion annually in the U.S., and recurring hospitalizations are the major cost driver.
ADVERTISEMENT


"The ability of Celacade to significantly reduce time in hospital, in conjunction with reducing the risk of death or cardiovascular hospitalization for this important group of heart failure patients, underscores the robustness and consistency of the ACCLAIM data," stated Dr. Torre-Amione, Medical Director, Heart Transplant Program, Methodist DeBakey Heart Center at The Methodist Hospital, and Principal Investigator for the U.S. arm of the ACCLAIM trial. "The need for repeated hospitalizations remains a persistent problem for heart failure patients, resulting in reduced quality of life and a major drain on healthcare resources. A therapy that not only reduces the risk of death or first cardiovascular hospitalization, but also reduces the total days spent in hospital by a similar magnitude, would be a welcome addition to the standard of care."

As presented by Dr. Torre-Amione today, a combined analysis of NYHA Class II-IV non-ischemic cardiomyopathy patients, characterized as having no prior history of heart attack, as well as Class II patients with ischemic etiology, demonstrated a 31% reduction in the risk of death or first cardiovascular hospitalization in the Celacade group compared to placebo (n=1,305 patients, 391 events, p=0.0003). New data presented today showed that, in these patients, Celacade also reduced total days in hospital for cardiovascular cause by 32% (n= 1,305 patients, p=0.013).

A combined analysis based on pre-specified subgroups, which excluded only those patients in NYHA Class III/IV with a left-ventricular ejection fraction equal to or below the median (LVEF<=23%) and a prior history of heart attack, showed that Celacade reduced the risk of death or first cardiovascular hospitalization by 21% (n=1,746 patients, 560 events, p=0.005). This finding, comprising 72% of the patients in the ACCLAIM study, demonstrates the consistency of Celacade's therapeutic effect in patients who have not progressed to late-stage disease. Based on the mortality and morbidity in this population, these patients are expected to form the target market for commercialization of Celacade in the European Union.

"The data from the ACCLAIM trial highlight the considerable commercial potential of Celacade in the treatment of a majority of chronic heart failure patients," stated David Elsley, President and CEO of Vasogen. "In light of the positive findings from ACCLAIM, preparations are now underway for a meeting with the FDA to discuss plans for regulatory submission of Celacade for approval in the United States. We are also making important progress in discussions with prospective marketing partners to support commercialization of Celacade in the European Union for the largest and fastest growing segment of the heart failure market."

Consistent with the impact of Celacade on the risk of mortality and morbidity in a majority of patients in the ACCLAIM trial was the finding of a significant improvement in quality of life (as measured by the Minnesota Living with Heart Failure Questionnaire) for the intent-to-treat study population (p=0.04). Celacade was also shown to be safe and well tolerated, and there were no significant between-group differences for any serious adverse events.

"Hospitalization remains the major cost associated with the ongoing care of chronic heart failure patients, and the new data presented today provide further evidence to support reimbursement and the adoption of Celacade into the standard of care in heart failure," said Dr. James Young, Chairman, The Cleveland Clinic Foundation, Medical Director, Kaufman Center for Heart Failure, and Chairman of the Steering Committee for the ACCLAIM trial. "Importantly, our overall findings clearly indicate that Celacade provided a significant risk reduction for a majority of the patient population in the ACCLAIM trial, excluding only those with advanced left-ventricular dysfunction and a history of cardiac damage due to heart attack - disease that is likely irreversible. We are looking forward to a meeting with the FDA to discuss plans for a formal application for regulatory approval of Celacade."

About the ACCLAIM Trial

The double blind, placebo-controlled ACCLAIM trial studied 2,408 subjects with chronic heart failure at 175 clinical centers in seven countries. ACCLAIM was designed to assess the ability of Celacade to reduce the risk of death or first cardiovascular hospitalization. Patients included in the study had New York Heart Association (NYHA) Class II, III, or IV heart failure with a left-ventricular ejection fraction (LVEF) of 30% or less and had been hospitalized or received intravenous drug therapy for heart failure within the previous 12 months, or had NYHA Class III/IV heart failure with a LVEF of less than 25%.

Patients in the ACCLAIM trial were receiving optimal standard-of-care therapy for heart failure, which at baseline included diuretics (94%), ACE-inhibitors (94%), beta blockers (87%), automatic implantable cardioverter defibrillators (26%), and use of cardiac resynchronization therapy (10.5%). The placebo (n=1,204 patients) and Celacade (n=1,204 patients) groups were well balanced for all important baseline characteristics, including demographics, LVEF, NYHA classification, concomitant medical conditions, medications, and device therapies.

The difference in time to death or first cardiovascular hospitalization (the primary endpoint) for the intent-to-treat study population was not statistically significant; however, the risk reduction directionally favoured the Celacade group.

About Chronic Heart Failure

Chronic inflammation is now well recognized as an underlying mechanism contributing to the development and progression of heart failure. Chronic heart failure is a debilitating condition in which the heart's ability to pump blood throughout the body is impaired. Patients with heart failure experience a continuing decline in their health, resulting in an increased frequency of hospitalization and in premature death.

About the Chronic Heart Failure Market

In North America and Europe, chronic heart failure affects approximately twelve million people, thirty three percent of whom have non-ischemic etiology. At any one time, approximately 4.4 million of these patients are in the NYHA Class II stage of disease and 2.4 million patients are NYHA Class III.

In the U.S. alone, the cost of medical care, primarily resulting from hospitalization, is estimated to exceed $25 billion annually and the condition is associated with more than 600,000 deaths each year. Currently, there are no approved therapies that target the chronic inflammation underlying chronic heart failure.

Old news from September 12 about tomorrow Conference presentation became to work - today VSGN raised up to 9.8%

Vasogen to Present at the A.G. Edwards' Emerging Growth Conference

MISSISSAUGA, ON, Sept. 12 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that its President and Chief Executive Officer, David Elsley, will present a Company overview at the A.G. Edwards' Emerging Growth Conference 2006 on Wednesday, September 20, at 10:30 a.m. ET at the New York Palace Hotel.

Bought back VSGN

past a buck in play if breakout on ascending triangle

in @ 0.71

down today, breakout from ascending triangle failed 
cheers
Oliver